In their letter, Labrinidis and colleagues raise the important issue of what (if any) might be the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in osteoclastogenesis. In previous studies, we 1,2 and 2 other independent groups of investigators [3] [4] [5] have shown that histidine-tagged (His-tag) recombinant TRAIL negatively regulates osteoclastogenesis by inhibiting preosteoclast differentiation and by inducing apoptosis of mature osteoclasts. On the other hand, Labrinidis et al were unable to confirm these previous findings when exposing osteoclastic cultures to the version of Apo2L/TRAIL that is currently being used in phase 1b clinical trials. Although Labrinidis et al emphasize the differences between the recombinant TRAIL preparations used in their and previous studies, 1-5 the possibility that the antiosteoclastic activity of TRAIL merely reflects an aspecific toxic effect of recombinant His-tag TRAIL is ruled out by 2 major considerations: (1) different groups of investigators have clearly documented the ability of recombinant His-TRAIL to induce in vitro prosurvival and even proliferative responses in a cell-type specific manner 6 ; and (2) Roux's group has recently demonstrated that native TRAIL, produced and released in vitro by end-stage osteoclasts, promotes osteoclastic apoptosis through autocrine/paracrine mechanism. 4 Thus, besides blocking receptor-activator of NF-B ligand (RANKL)-mediated osteoclastogenesis, osteoprotegerin (OPG) seems also able to protect mature osteoclasts from apoptosis mediated by native TRAIL endogenously produced by osteoclasts. 4 These findings corroborate the hypothesis that the relative concentrations of RANKL, OPG, and TRAIL at the local bone marrow level are critical for determining the fate of osteoclasts. 6, 7 The net effect of TRAIL on osteoclastic differentiation and survival likely depends on the network of prosurvival and proapoptotic signals operating at a given time in the bone marrow microenvironment. In this respect, it should be considered that the antiosteoclastic activity of TRAIL reported by our and other groups 1-5 was observed in culture conditions in which purified populations of preosteoclasts were induced to differentiate along the osteoclastic lineage by adding recombinant macrophage-colony stimulating factor (M-CSF) plus RANKL to the culture medium. On the other hand, Labrinidis et al have cultured peripheral blood mononuclear cells (used as a source of preosteoclasts) in the presence also of vitamin D3 and dexamethasone, which are known to potently promote osteclastic survival and differentiation. 8 Thus, in our view, the novel contribution of the findings of Labrinidis et al with respect to previous data 1-5 relies on the demonstration that the presence in culture of vitamin D3 and dexamethasone abrogates the antidifferentiative and proapoptotic activities of TRAIL. However, this does not exclude a role of TRAIL in osteoclastogenesis, as suspected by Labrinidis et al, but rather suggests a level of molecular control on the antiosteoclastic activity of TRAIL.
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Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis
Erdheim-Chester disease (ECD) is a non-Langerhans form of CD68 ϩ CD1a Ϫ histiocytosis. [1] [2] [3] [4] Interferon ␣ (IFN␣) is effective in ECD. 3, 5 Efficacy is however depending on the site of involvement. Central nervous system (CNS) and cardiovascular involvement do not respond to IFN␣ and have a poor prognosis. 5 Two patients suffering from Langerhans cell histiocytosis (LCH) and Rosai-Dorfman disease histiocytosis (RDD) were dramatically improved with imatinib mesylate (IM), a tyrosine kinase inhibitor, which selectively inhibits bcr-abl, KIT and platelet-derived growth factor (PDGF). 6,7 IM, initially given at 100 mg/d and raised to 400 mg/d after 1 month dramatically improved LCH cerebral infiltration, 6 and, for the multisystemic RDD patient, 7 the manifestations almost completely resolved under 600 mg/d within 6 weeks. Rationale for the use of IM was the For personal use only. on April 14, 2017. by guest www.bloodjournal.org From expression of PDGF receptor beta (PDGFr-␤) on histiocytes and the inhibition of PDGF kinases by IM. [8] [9] [10] PDGFr-␤ (Santa Cruz Biotechnology, Santa Cruz, CA) expression was studied on tissue samples from various origins of 37 ECD patients, 11 LCH patients, and 4 RDD by immunostaining on formalin-fixed, deparaffinized 4-m tissue sections, using commercial kits, LSAB, or the EnVisionϩDAB system, and an automated immunostainer, according to the manufacturer's instructions (Dako North America, Carpinteria, CA). In 32 of 37 samples (86.5%)-the largest monocentric pathologic analysis of ECD-a positive PDGFr-␤ expression on histiocytes was observed. Three of the 11 LCH biopsies (27.3%) had histiocytes positive for PDGFr-␤. None of the 4 specimens from RDD patients was positive for PDGFr-␤.
Six of the 32 ECD patients positive for PDGFr-␤, whose disease was severe, potentially life-threatening, multisystemic, and/or refractory to conventional therapy (including IFN␣ and/or autologous stem cell transplantation) were treated with IM (see Table 1 ). All 6 patients, followed at the Internal Medicine Department of Pitié-Salpêtrière Hospital, provided written informed consent in accordance with the Declaration of Helsinki. The medical decision to propose a treatment by IM was taken after a collegial discussion, justified by the severity of the disease in all cases and by the resistance to other treatments in 3 cases. The initial dose was 100 mg/d, increasing progressively according to tolerance and treatment efficacy. In one patient, the maximum dose reached was 800 mg/d. Five of the 6 patients received IM only. Median follow-up after IM initiation was 12.5 months (range: 6-24 months) and the maximal median daily dose was 350 mg/d. On the basis of the clinical and the radiologic outcomes, physicians (J.H. and Z.A.) judged the disease was globally "stable" in 2 and "worsening" in 4 cases. Studying the evolution of the "site by site" ECD manifestation under IM we found different response rate according to the sites of involvement. While CNS manifestations often worsened (75%), cardiovascular involvement remained stable in most of the cases (80%). IM was safe, with no major side effects observed.
The sample size of our study is large enough to draw firm conclusions on the almost unvariable presence of PDGFr-␤ on histiocytes of ECD. Our data, and those previously reported, suggest that the PDGFr-␤ expression is much more variable in LCH and RDD. Even though IM does not seem to be efficacious in ECD, we cannot rule out a partial efficacy on cardiovascular involvement. It is possible that several patients were too severe to show improvement at the time of treatment initiation, especially those with long-term lasting CNS involvement (case nos. 2, 3, and 5). In some cases doses of IM might not have been high enough (case nos. 1, 4, and 5) compared with higher doses that were given in RDD (400 to 600 mg/d). 7 Tyrosine kinase inhibitors more specific of the PDGFr-␤ could therefore be promising drugs for the treatment of patients with severe forms of ECD resistant to IFN␣ therapy.
